SK Chemicals, a pharmaceutical affiliate of South Korean conglomerate SK Group, on Sunday said it has submitted its patch-type Alzheimer’s drug SID710 to the U.S. Food and Drug Administration for approval.
SID710 is a generic drug referencing Novartis’ Exelon Patch (rivastigmine), a transdermal medication to treat dementia symptoms associated with Alzheimer’s disease.
SK Chemicals` patch-type Alzheimer`s medication S170 (SK Chemicals)
The Korean drug maker expects the FDA to grant approval in 2018. “We expect the drug to pass through all the review procedures without trouble,” a SK Chemicals spokesperson told The Korea Herald.
SK’s drug was already approved in the European Union in 2013. It currently sells the drug in 13 states in the region, including the U.K., France, Germany and Spain. SID710 takes up around 50 percent of the region’s Exelon Patch generics market, according to the firm.
If approved in the U.S., SID710 will take on the country’s transdermal Alzheimer’s medication market, which generated sales of around $618 million in 2015, according to market analyst IMS Health.
By Sohn Ji-young (
jys@heraldcorp.com)
